Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer. - Wikidata - thesis-toulmin - TriplyDB

Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

http://www.wikidata.org/entity/Q37056923

about

Metastatic axillary node ratio predicts recurrence and poor long-term prognosis in patients with advanced stage IIIC (pN3) breast cancer Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis.

P2860

Q33636187-E12992ED-2945-42D3-BBF5-8EF936BF8352 Q45284997-1D379A02-EDFD-4327-BDD9-4AE3EC673D6C

P2860

Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

http://www.wikidata.org/entity/Q37056923

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

@en

Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

@nl

type

label

Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

@en

Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

@nl

prefLabel

Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

@en

Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

@nl

P1433

Q37056923-1CFF3C7F-B2DA-48A6-B7BA-97DFD6945707

P1476

Q37056923-281996ED-09B1-4760-A29A-1AEC506F94C1

P2093

Q37056923-43603DA4-2824-4201-85A8-507547AB6DD6

Q37056923-64261EB0-AE26-4FDC-9988-D440B12FAF29

Q37056923-6F8530A4-1420-4FB9-8127-A36DB81D9915

Q37056923-9D8FB8F8-5F53-4911-A36F-EA1C8516DB75

Q37056923-B8E1C18E-5B44-44C7-99E3-2ED229BD6CAE

P2860

Q37056923-07EA2BBF-832E-4111-A756-555A55A91E32

Q37056923-0C408505-7835-48A1-A351-D55514044FD9

Q37056923-13F030EA-41E1-48A3-82D1-0A75622D75F8

Q37056923-2A0A5AED-FC40-4984-BD6A-2C0AFDC9BE4C

Q37056923-2B24CA80-C6EA-4520-A90D-1245715C875B

Q37056923-3AD805A2-4141-4FD8-A573-FE84961175F4

Q37056923-58503187-F437-4C1B-809D-96D4DBE50E58

Q37056923-5B4C0370-7A2C-4BA6-A53A-09410A25627F

Q37056923-63743BB2-D827-4209-9A77-204C1EF2F7B2

Q37056923-7BB38282-9164-4F30-99B6-6BCBF404B353

P304

Q37056923-B4685C80-7E94-46BA-BF38-0085640F1E0C

P31

Q37056923-D63D6AAE-9E72-4381-852F-E32D90DEB0A3

P356

Q37056923-E81CC50D-7A1E-4657-9DAE-A867173C423C

P433

Q37056923-FB5A8CF8-CF79-4B15-B8ED-31C00609962D

P478

Q37056923-767F8C77-29FC-4C95-9950-A43F05CF4CD9

P577

Q37056923-41399168-CF2E-4594-8760-83C9665BE868

P698

Q37056923-EEF674AA-E3EC-4F5B-9479-471BF1246FD6

P932

Q37056923-F38FF32E-E8EC-4662-9879-AE931C1AC0B5

P356

JBC.2016.19.2.163

P1433

Journal of breast cancer

P1476

Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

@en

P2093

Heung Kyu Park

http://www.w3.org/2001/XMLSchema#string

Kwan Il Kim

http://www.w3.org/2001/XMLSchema#string

Kyung Hee Lee

http://www.w3.org/2001/XMLSchema#string

Yong Soon Chun

http://www.w3.org/2001/XMLSchema#string

Yun Yeong Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.

Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system.

Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base.

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.

Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?

Correlation between Ki67 and breast cancer prognosis.

The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.

P304

163-168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4048/JBC.2016.19.2.163

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27382392

http://www.w3.org/2001/XMLSchema#string

P932

4929257

http://www.w3.org/2001/XMLSchema#string